NDAQ:INO - Post Discussion
Post by
7Twiggy on Feb 11, 2021 7:58pm
post from Yahoo finance
"Oppenheimer analyst Hartaj Singh initiated coverage of Inovio Pharmaceuticals with an Outperform rating and $35 price target. The stock in after-hours trading is up 6%, or 80c, to $13.80. Inovio's COVID-19 vaccine has a "differentiated profile and is moving closer to the finish line," Singh tells investors in a research note titled "A DNA Medicines Disruptor Gaining Steam." The company also has a "unique cancer vaccine with intriguing early-stage efficacy" in glioblastoma, adds the analyst. Singh says that while COVID-19-focused INO-4800 has been the high-profile candidate, Inovio's overall DNA platform "should not be overlooked." The analyst is bullish on the company's approach. INO-4800 has a better safety and tolerability profile that could generate higher uptake in a low-risk population, easier storage favored by stockpile, and potential flexibility to adjust for mutations, Singh contends."
Pretty well respected analyst and his overall performance has been good. Saying all the right things that we've known for awhile.
What struck me as funny though is the timing of this anouncement since there are TONS of call options with a 2/19 expiration written at $15, $16, $20, $21 and $26. Let's say if this runs to $30 next week (is feasible with this recommendation and short sales covering); someone will be making many many million dollars on owning these calls. (On 2/19 $20 calls alone there are 31,000 contracts @100 share per contract that would mean those calls with INO at $30 would be worth $31 million $$ and that's just the $20's.)
Let it run to $30 next week....I'm not complaining!
Be the first to comment on this post